AstraZeneca India’s Post

AstraZeneca India is at the forefront of science and innovation to address some of the biggest healthcare challenges in our country for greater resilience.    Every day, we relentlessly pursue scientific advancement to create enduring value for people, society and the planet. With our unwavering commitment to developing life-changing medications across all our therapeutic areas, we firmly believe that science is the cornerstone of revolutionary healthcare with sustainability in mind.    As an organization guided by science and driven by values, we recognize the transformative potential of scientific advancements in reshaping the healthcare landscape.    Watch the video to hear it from some of our leaders! #ScienceCan Dr. Sanjeev Panchal Praveen Rao Akkinepally Ramesh Varadarajan

Unlocking the power of what science can do

With 'Health Industry Report India 2024' coming up in Forbes India, Executive Forecast sat down with Dr. Sanjeev Panchal to capture the journey of AstraZeneca in India for the past 45 years and its purpose to transform healthcare in the country. Read on to see how we are harnessing science to create novel therapies and vaccines, make them accessible FASTER to patients in India. Help people with chronic diseases live better, healthier lives. Redefine cancer care. And pioneer treatments for rare diseases.

As AstraZeneca India marks #45Years of driving science-based innovation, we take immense pride in our journey of fostering a healthier tomorrow. Since 1979, we've been dedicated to pushing the boundaries of #science, delivering life-changing medicines to address India's most pressing health challenges.    Our unwavering commitment to research and development has paved the way for innovative treatments, making significant strides across our therapy areas. Beyond advancing medical solutions, we remain deeply committed to the larger purpose of tackling critical global challenges such as climate change, healthcare accessibility, and disease prevention.   Our legacy is not just about scientific excellence but also our dedication to the well-being of people, society, and the planet. At the heart of our success lies a culture of #inclusion and equity, where every individual is valued and empowered.   As we celebrate #45years of scientific rigor, togetherness, and well-being, we look forward to continuing our legacy of care and #innovation. Here's to creating a healthier future for generations to come.    #Fabulous45 #ScienceCan #PoweredbyPurpose

AstraZeneca is on a mission to transform the landscape of healthcare in the Middle East and Africa and specifically across #NearEast and #NorthAfrica through equity-driven initiatives like #CancerCareAfrica. By addressing healthcare disparities, we ensure that innovative care is accessible to those in need. Through this holistic approach, we aim to identify immediate health needs and build a foundation for sustainable healthcare systems. As we recognise World Health Day, this year's theme, #MyHealthMyRight reinforces our commitment to health equity. It emphasises the necessity of our efforts to extend healthcare access across diverse communities, challenging us to innovate and collaborate more effectively. Today, let us renew our dedication to making health equity a cornerstone of our work. World Health Day is a powerful reminder of our shared mission to ensure that everyone, regardless of their circumstances, has the right to quality healthcare. Together, we can achieve a healthier future for all. #HealthEquity #WorldHealthDay #NEMAG #Maghreb #AstraZeneca Qutaiba Al Manaseer Abdulkareem Al Dissi Chloe Jolley Maria Nauss

Abbott India: A Journey to the Top Abbott India has firmly established itself as one of the top two pharmaceutical companies in India. Here’s a look at their incredible journey: Early Beginnings: Founded in 1910 by Dr. Wallace Calvin Abbott, a Chicago physician, Abbott began its journey with a mission to discover, develop, and deliver innovative medicines. The company entered the Indian market in the 1940s, establishing its first office in Mumbai. Growth and Expansion: Over the decades, Abbott India expanded its footprint, focusing on innovative healthcare solutions. The company introduced numerous groundbreaking products, addressing critical health needs across various therapeutic areas including women’s health, gastroenterology, cardiology, and metabolic disorders. Commitment to Quality: Abbott's commitment to quality and safety has been a cornerstone of its success. By investing in cutting-edge research and development, the company has consistently delivered high-quality, effective, and safe medications. Strategic Acquisitions: Key strategic acquisitions played a significant role in Abbott India's growth. Acquiring Piramal Healthcare’s Healthcare Solutions business in 2010 significantly boosted Abbott's presence in India, enabling it to reach a broader audience and expand its portfolio. Innovation and R&D: Abbott India's state-of-the-art R&D centers and manufacturing facilities underscore their commitment to innovation. These centers focus on developing new formulations and improving existing ones, ensuring that they meet the highest global standards. Community Engagement: Beyond business, Abbott India has been actively involved in community health initiatives. Programs focused on nutrition, maternal health, and chronic disease management have made a positive impact on millions of lives. Recognition and Awards: Abbott India’s dedication to excellence has been recognized with numerous awards and accolades over the years. These honors reflect the company’s relentless pursuit of quality and innovation. Looking Ahead: As Abbott India continues to grow, its mission remains clear: to provide trusted medicines that help people live healthier, fuller lives. With a robust pipeline of new products and a commitment to addressing emerging health challenges, Abbott India is poised for continued success. Abbott India’s story is one of dedication, innovation, and a steadfast commitment to improving health outcomes. Here’s to their continued success in transforming lives and leading the pharmaceutical industry in India! #AbbottIndia #Pharmaceuticals #Healthcare #Innovation #Leadership #TopPharm

At AstraZeneca, we are constantly pushing the boundaries of science to deliver life-changing medicines. But we can’t do this alone, so our way of working is inclusive, open and collaborative. We are proactively making a societal impact through our ‘Inclusion & Diversity’ (I&D) approach, endorsing that true innovation stems from a diverse perspective empowered to challenge conventional thinking. Continuously, we reaffirm our commitment to creating an inclusive and equitable environment while fostering diversity as a competitive advantage to deliver life-changing medicine.  We recognize that there is more we can do to accelerate change to benefit our employees, patients, and the communities we support and to achieve more equitable, and sustainable healthcare ecosystems. #BreakingBarriers #GreatPlaceToWork #InspireInclusion

📈 Abbott (ABT) Outperforms Market Expectations! 🌟 Great news for investors and stakeholders! Abbott (ABT) has exceeded market returns, showcasing its resilience and robust performance in the healthcare sector. 🌐 Key Highlights: -Abbott's strategic initiatives and innovative product launches have driven this impressive growth. -Consistent focus on expanding their medical device and diagnostics portfolios has paid off significantly. -The company's strong financial performance is a testament to its commitment to improving global health. -This achievement underscores Abbott's position as a leader in the healthcare industry, continuously delivering value to its shareholders and making impactful contributions to medical advancements. 🚀 Let's celebrate this milestone and look forward to more groundbreaking achievements from Abbott! #Abbott #MarketPerformance #HealthcareInnovation #InvestmentSuccess #MedicalDevices #Diagnostics #GlobalHealth #FinancialGrowth #StockMarket #InvestorNews

On the 25th anniversary of the merger between Astra and Zeneca, AstraZeneca Türkiye shared a comprehensive report evaluating AstraZeneca's economic and social impacts in Türkiye. According to the "Impact of AstraZeneca on Türkiye" Report, the actual value of the company's total GDP impact on Türkiye over 25 years, considering both indirect and induced effects, totals 195 billion TL, supporting an additional 11 jobs in the economy for every job provided. Serkan BARIS, Country President of AstraZeneca Türkiye, who underlined their perseverance in improving health outcomes globally and in Türkiye, said, "Türkiye is a crucial country within our global and regional structure. We are one of the largest international pharmaceutical companies in Türkiye. With over 500 employees, we provide services based on our treatment areas and have a presence in 29 geographical regions. We are not just a part of the healthcare ecosystem; we are a solution partner within this ecosystem. While enhancing health outcomes with our potent medications, we actively participate with stakeholders in developing healthcare service processes." Dr. Deniz Erturk Erem, the Medical Director of AstraZeneca Türkiye, emphasized their belief that a healthier society and a sustainable healthcare system can be achieved through stakeholder collaboration. She said, "We support many initiatives in our country's healthcare ecosystem that endorse innovative solutions, including universities and medical associations." She added, "We collaborate with many centers across Türkiye to generate and support the production of real-life data to contribute to fields such as heart failure, chronic kidney disease, asthma, lung cancer, and more." Erdal Kiraz, the Director of Corporate Affairs at AstraZeneca Türkiye, highlighted that their efforts extend beyond drug development and healthcare service provision to addressing societal issues. He stated, "AstraZeneca's work in the social impact domain includes focusing on areas such as improving access to healthcare, enhancing education, promoting health literacy, addressing societal needs in disasters and other emergencies, promoting diversity and inclusivity, and managing environmental impacts. Additionally, we work to facilitate access to primary healthcare services, raise awareness about public health, and expand activities such as screening." #socialimpact #economicimpact #scientificimpact  #AstraZenecaTürkiye #25thAnniversary #AstraZeneca #WhatScienceCanDo

🇸🇪𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗦𝘄𝗲𝗱𝗲𝗻: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗠𝗮𝗻𝗮𝗴𝗲𝗱 𝗘𝗻𝘁𝗿𝘆 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 (𝗠𝗘𝗔𝘀)🇸🇪 How are MEAs reshaping access to novel therapies in Sweden? In Sweden, MEAs are now central tools for ensuring access to innovative therapies while managing healthcare costs. Currently, 𝗼𝘃𝗲𝗿 𝗵𝗮𝗹𝗳 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗮𝗹𝗲𝘀 𝗮𝗿𝗲 𝗰𝗼𝘃𝗲𝗿𝗲𝗱 𝗯𝘆 𝗠𝗘𝗔𝘀, which often use confidential rebates and outcome-based payments to balance affordability and value. 🔍 𝗛𝗼𝘄 𝗠𝗘𝗔𝘀 𝗪𝗼𝗿𝗸  MEAs complement Sweden’s value-based pricing system for outpatient drugs, addressing uncertainties around costs and patient volumes while allowing flexibility for local needs through three key players: • 𝗧𝗟𝗩 (𝗗𝗲𝗻𝘁𝗮𝗹 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗔𝗴𝗲𝗻𝗰𝘆): Sets national standards for cost-effectiveness and access. • 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀: Negotiate agreements to align with local budgets and healthcare priorities. • 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: Collaborate to support both access and cost containment. 🚀 𝗙𝘂𝘁𝘂𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀  With drug costs rising around 5% annually, MEAs are increasingly critical for maintaining sustainable access to high-cost therapies. TLV is exploring new MEA models, including outcome-based payments, to better support advanced therapies. 📊 𝗣𝗼𝗹𝗶𝗰𝘆 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆  𝗘𝗾𝘂𝗮𝗹 𝗮𝗰𝗰𝗲𝘀𝘀 is a cornerstone of Sweden’s healthcare system and remains high on the political agenda. While MEAs can accelerate access to innovative therapies, Sweden’s decentralized healthcare model—where regional authorities negotiate MEAs—can lead to variations in access across regions. The government is considering steps to centralize certain aspects of medicine access to ensure equitable access across all regions. 📈 𝗪𝗵𝗮𝘁 𝗧𝗵𝗶𝘀 𝗠𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀  For companies entering the Swedish market, understanding both TLV’s value-based pricing approach and the nuances of regional MEA negotiations is essential. Monitoring policy developments toward national coordination will also be crucial. Balancing cost-effectiveness with equitable access will continue to be fundamental—especially for high-cost, innovative therapies. Interested in navigating MEAs and staying ahead of policy changes in Sweden? 📩 Contact Charlotte Langbo and Elisabetta Cesari to discuss how we can help you navigate these complexities and optimize access to your innovative products in Sweden! Contribution by Elisabetta Cesari, our Senior Associate at Inbeeo! #ManagedEntryAgreements #MarketAccess #InnovativeTherapies #Sweden #EquitableAccess